Press release
United States Targeted Therapy DataM Market Intelligence Competitive Landscape & Forecast to 2025 | Industry Report
Targeted Therapy
For example, F. Hoffmann-La Roche Ltd, a major player in the targeted therapy market, earned 33.71% of its revenue from the U.S., driven by sales of its HER2 inhibitors portfolio (total sales: US$ 9,928.20 million; U.S. sales: US$ 3,347.29 million).
According to the International Agency for Research on Cancer, there were approximately 20 million new cancer cases worldwide in 2022, with projections rising to about 24.1 million by 2030 and 29.9 million by 2040. For example, the targeted therapy drug trastuzumab, marketed as Enhertu, costs around US$ 3,142.90 per injection vial, imposing a substantial financial burden on patients, healthcare systems, and insurers, HER2, EGFR, VEGF, or CD antigens
These drugs, including Trastuzumab (Herceptin), Pertuzumab (Perjeta), Trastuzumab deruxtecan (Enhertu), and Trastuzumab emtansine (Kadcyla), rank among the top-selling targeted cancer therapies. Acting as targeted therapeutics, they are categorized into VEGF inhibitors, CD antigen-targeted mAbs, EGFR inhibitors, HER2 inhibitors, and more. These monoclonal antibodies are used to treat a variety of cancers, including breast, colorectal, leukemia, gynecological, lung, liver, and head and neck cancers.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/targeted-therapy-market?kb
List of Top Key Player:
F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., AstraZeneca, Eisai Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company., Incyte, Eli Lilly and Company, and Exelixis, Inc., among others.
Industry Developments:
In May 2025, the U.S. FDA granted accelerated approval to EMRELIS (telisotuzumab vedotin-tllv) by AbbVie for adults with locally advanced or metastatic non-squamous NSCLC overexpressing c-Met after prior therapy.
In March 2025, Genmab A/S announced Japan's approval of TIVDAK (tisotumab vedotin) for advanced or recurrent cervical cancer post-chemotherapy.
In October 2024, Genentech (Roche Group) received FDA approval for Itovebi (inavolisib) with palbociclib and fulvestrant to treat endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Forecast Projection:
The Global Targeted Therapy Market is poised for significant growth between 2025 and 2032. In 2024, the market maintained a steady upward trajectory, and with strategic initiatives by leading players accelerating adoption, the market is expected to soar throughout the forecast period. Companies leveraging these trends are well-positioned to capture emerging opportunities and maximize revenue potential.
Market Intelligence Research Process:
The Targeted Therapy Market research report by DataM Intelligence combines primary and secondary data to deliver deep, actionable insights. It examines the full spectrum of factors shaping the industry, from government regulations and market conditions to competitive dynamics, historical trends, technological breakthroughs, upcoming innovations, and potential challenges. This comprehensive analysis not only highlights growth prospects but also identifies barriers, equipping businesses to navigate market volatility and capitalize on emerging opportunities.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=targeted-therapy-market
Key Segmentation:
Monoclonal antibodies held 62.5% of market share in 2024
By Type: Monoclonal Antibodies, VEGF Inhibitors, Antibody Drug Conjugates, CD Antigen-Targeted mAbs, EGFR Inhibitors, HER2 Inhibitors, Others, Small Molecules, PARP Inhibitors, Tyrosine Kinase Inhibitors, BRAF/MEK inhibitors, CDK Inhibitors, Others
By Indication: Leukemia, Breast Cancer, Lung Cancer, GI Cancers, Melanoma, Others
By Route of Administration: Oral, Parenteral
Global Growth Regional Analysis:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
Chapter 1 - Market Overview: Kickstarts the report with a comprehensive snapshot of the Targeted Therapy Market, summarizing key segments by region, product type, and application. Highlights include market size, segment growth potential, and short- & long-term industry outlook.
Chapter 2 - Emerging Trends: Uncovers the game-changing trends and high-impact innovations shaping the future of the industry.
Chapter 3 - Competitive Landscape: Offers a deep dive into market competition, detailing revenue shares, strategic initiatives, and recent mergers & acquisitions.
Chapter 4 - Top Player Profiles: Features detailed company profiles, covering revenue, profit margins, product lines, and major milestones for leading market players.
Chapters 5 & 6 - Regional & Country Analysis: Breaks down revenue performance across global regions, providing insights on market sizes, opportunities, and growth prospects worldwide.
Chapter 7 - Segmentation Analysis: Explores market segmentation by type, revealing high-potential categories and guiding businesses towards lucrative areas.
Chapter 8 - Application Insights: Examines downstream markets and identifies promising sectors for expansion, showing how different applications are driving growth.
Chapter 9 - Supply Chain Mapping: Maps the entire industry supply chain, highlighting upstream and downstream activities for a holistic market perspective.
Chapter 10 - Key Takeaways: Concludes with critical insights and actionable strategies, equipping stakeholders to make informed decisions and stay ahead in the market.
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/targeted-therapy-market?kb
FAQ's
Q1: What is the current size of the Targeted Therapy Market and its future potential?
A: The Targeted Therapy Market was valued at US$ 79.18 billion in 2024 and is projected to surge to US$ 147.16 billion by 2033
Q2: How fast is the Targeted Therapy Market expected to grow in the coming years?
A: The market is forecast to expand at a robust CAGR of 7.2% between 2025 and 2032, signaling strong global growth and investment potential.
Q3: Which regions are dominating the Targeted Therapy Market and which are fastest-growing?
A: North America dominating the Targeted Therapy market.
Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?kb
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Targeted Therapy DataM Market Intelligence Competitive Landscape & Forecast to 2025 | Industry Report here
News-ID: 4209194 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Smart Factory Market to Reach US$ 290.6 Billion by 2033 at 12.6% CAGR; North Ame …
The Global Smart Factory Market reached US$ 112.4 billion in 2024 and is expected to reach US$ 290.6 billion by 2033, growing at a CAGR of 12.6% during the forecast period 2025-2033. Market growth is driven by increasing adoption of Industry 4.0 practices, rising demand for automation and operational efficiency, and growing integration of digital technologies across manufacturing industries.
Smart factories leverage advanced technologies such as the Industrial Internet of Things…
Radiofrequency Ablation Devices Market to Reach US$ 13.54 Billion by 2033 at 10. …
The Global Radiofrequency Ablation Devices Market reached US$ 5.63 billion in 2024 and is expected to reach US$ 13.54 billion by 2033, growing at a CAGR of 10.7% during the forecast period 2025-2033. Market growth is driven by the rising prevalence of chronic pain conditions and cancer, increasing preference for minimally invasive procedures, and advancements in ablation technologies.
Radiofrequency ablation devices are used to treat tumors, cardiac arrhythmias, and chronic pain…
Mobile Threat Defense (MTD) Market to Reach US$ 10.5 Billion by 2030, Growing at …
According to DataM Intelligence, the global Mobile Threat Defense (MTD) market reached US$ 2.2 billion in 2022 and is expected to reach US$ 10.5 billion by 2030, growing at a CAGR of 22.0% during the forecast period 2024-2031. This growth is propelled by the rapid surge in mobile malware, phishing, and ransomware attacks targeting enterprises, increasing adoption of BYOD and remote work policies, strong demand for cloud-based MTD solutions, rising…
Digital Identity Solutions Market to Reach US$ 189.92 Billion by 2033 at 20.45% …
The Global Digital Identity Solutions Market reached US$ 35.50 billion in 2023 and increased to US$ 42.45 billion in 2024, and is expected to reach US$ 189.92 billion by 2033, growing at a CAGR of 20.45% during the forecast period 2025-2033. Market growth is driven by the rising need for secure identity verification, increasing digitalization across industries, and growing concerns over identity fraud and data security.
Digital identity solutions enable the…
More Releases for Targeted
Targeted Alpha Therapy Market
Global Targeted Alpha Therapy Market Size, Drugs Approval, Proprietary Technologies & Clinical Trials Insight 2028 Report Highlights:
• Global Targeted Alpha Therapy Market Insight By Region
• Approved Targeted Alpha Therapy Dosage & Pricing Insight
• Number Of Targeted Alpha Therapy In Clinical Trials: > 20 Drugs
• Targeted Alpha Therapy Clinical Trials Insight By Company, Country, Indication & Phase
• Marketed Targeted Alpha Therapy Clinical Insight By Company, Country & Indication
• Targeted Alpha Therapy Proprietary Technology Platform Insights By…
Dark Truth Behind Targeted Violence
Intimidation and cyberbullying public bullying the (target)victims selected into committing the violent criminal acts if the victims mentality was broken.
The perpetrators are small fraud groups organizing misinformation with false profiles for the public to participate with public bullying while the groups stalk the victim.
San Diego California 2021-2024 plot failed federal agents on standby monitoring the targets failed at there duties of integrity while presidential elections push towards Nov 5 San…
Bispecific Antibodies: Revolutionizing Targeted Cancer Therapy
Bispecific antibodies (BsAbs) are revolutionizing targeted cancer therapy by offering a dual-targeting approach that enhances therapeutic efficacy and addresses tumor heterogeneity. These engineered antibodies are designed to recognize and bind two different antigens simultaneously, providing a more comprehensive attack on cancer cells and improving treatment outcomes.
One of the most successful examples of BsAbs is blinatumomab, which targets CD19 on B-cells and CD3 on T-cells. Blinatumomab has shown remarkable efficacy in…
Targeted Email Leads: Pioneering a New Era in Email Marketing with High-Quality, …
GREENSBORO, NC - 15 August 2024 - In the rapidly evolving digital landscape, one company is setting new standards in email marketing. Targeted Email Leads, a trailblazer in the provision of precision-targeted email lists, is offering meticulously cleaned and verified lists that cater to a wide range of applications, from B2B communications to consumer engagement and interest groups.
What sets Targeted Email Leads apart is their rigorous verification process. Each…
Tetravalent Antibody as Cancer Targeted Therapy
The advent of tetravalent antibodies marks a significant breakthrough in cancer targeted therapy, offering a sophisticated approach to tackling the complex and heterogeneous nature of tumors. These antibodies, engineered to bind to four distinct antigens or epitopes simultaneously, provide enhanced specificity and efficacy, addressing the limitations of traditional monoclonal and even bispecific antibodies.
Download Bispecific, Trispecific and Tetraspecific Antibodies Report:
https://www.kuickresearch.com/ccformF.php?t=1721642510
Cancer is a multifaceted disease characterized by diverse cell populations within a…
Targeted Advertising Solutions Market - Rising Demand from the Providers of Targ …
The rising popularity of digital channels such as mobile and online for media and entertainment, and communications, coupled with their capability to identify and benefit from tracking customer behavior accurately, have created major interest and increasing investments by advertisers on targeted advertising.
Download PDF Brochure For Future Advancements@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=47862
Organizations making an entry into the advertising value network need to effectively educate, engage, and create alertness to the advantages of targeted…
